Want to see JP:2413 full AI Analyst Report?
2413 Stock Chart & Stats
¥1904.50
¥16.00(0.84%)
At close: 4:00 PM EDT
¥1904.50
¥16.00(0.84%)
Day’s Range― - ―
52-Week Range¥1,297.00 - ¥2,746.00
Previous CloseN/A
Volume3.52M
Average Volume (3M)2.99M
Market Cap
¥1.04T
Enterprise Value¥1.12M
Total Cash (Recent Filing)¥156.18B
Total Debt (Recent Filing)¥33.15B
Price to Earnings (P/E)22.4
Beta0.57
Next Earnings
Oct 22, 2026EPS Estimate
19.12Next Dividend Ex-DateN/A
Dividend Yield1.43%
Share Statistics
EPS (TTM)72.52
Shares Outstanding679,124,800
10 Day Avg. Volume2,689,370
30 Day Avg. Volume2,988,500
Financial Highlights & Ratios
PEG Ratio1.02
Price to Book (P/B)2.66
Price to Sales (P/S)3.09
P/FCF Ratio17.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,084.29Price Target Upside9.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)80.33
Revenue Forecast (FY)¥391.65B
Bulls Say, Bears Say
Bulls Say
Re-accelerating Revenue GrowthSustained top-line re-acceleration to mid-teens indicates durable demand for M3’s healthcare platforms and services. Over a 2–6 month horizon this supports predictable revenue scaling, strengthens customer retention economics across pharma and clinician networks, and underpins reinvestment capacity.
Strong Free Cash Flow GenerationHigh FCF conversion near parity with earnings signals strong cash generation and earnings quality from platform and services businesses. Durable free cash flow provides flexibility for R&D, M&A or shareholder returns and improves resilience against cyclical swings in project timing.
Conservative Balance Sheet / Low LeverageVery low leverage and growing equity create financial flexibility for strategic investment and downside protection. A conservative capital structure reduces refinancing risk, supports steady investment in platform capabilities, and strengthens the company's capacity to pursue opportunistic expansion.
Bears Say
Margin Compression Vs Prior YearsEroding margins signal either rising cost pressure or a less favorable revenue mix; over months this can reduce internal cash available for growth investments and weaken competitive returns. Persistent compression would strain long-term profitability despite revenue growth.
Uneven Operating Cash Flow ConversionVariability in OCF conversion suggests working-capital timing or project billing lags that can make cash less predictable. Over a multi-month horizon this can complicate capital allocation, increase reliance on cash reserves for timing gaps, and limit the pace of reinvestment.
Earnings Below 2022 Peak; ROE Trended DownAlthough returns remain acceptable, the decline from prior peaks indicates the company faces structural headwinds to restore earlier profitability levels. If trends persist, long-term return on invested capital could weaken investor optionality and constrain growth funded from internal returns.
M3 News
2413 FAQ
What was M3 Inc’s price range in the past 12 months?
M3 Inc lowest stock price was ¥1297.00 and its highest was ¥2746.00 in the past 12 months.
What is M3 Inc’s market cap?
M3 Inc’s market cap is ¥1.04T.
When is M3 Inc’s upcoming earnings report date?
M3 Inc’s upcoming earnings report date is Oct 22, 2026 which is in 71 days.
How were M3 Inc’s earnings last quarter?
M3 Inc released its earnings results on Aug 06, 2026. The company reported ¥13.6 earnings per share for the quarter, missing the consensus estimate of ¥20.087 by -¥6.487.
Is M3 Inc overvalued?
According to Wall Street analysts M3 Inc’s price is currently Undervalued.
Does M3 Inc pay dividends?
M3 Inc pays a Annually dividend of ¥22 which represents an annual dividend yield of 1.43%. See more information on M3 Inc dividends here
What is M3 Inc’s EPS estimate?
M3 Inc’s EPS estimate is 19.12.
How many shares outstanding does M3 Inc have?
M3 Inc has 679,124,800 shares outstanding.
What happened to M3 Inc’s price movement after its last earnings report?
M3 Inc reported an EPS of ¥13.6 in its last earnings report, missing expectations of ¥20.087. Following the earnings report the stock price went up 6.11%.
Which hedge fund is a major shareholder of M3 Inc?
Currently, no hedge funds are holding shares in JP:2413
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
M3 Inc
M3, Inc. is a Japanese company that delivers a broad spectrum of internet-based services, predominantly catering to medical professionals and the broader healthcare industry. Its operations are segmented into five key areas: Medical Platform, Evidence Solution, Career Solution, Site Solution, and Overseas. M3 manages several specialized online platforms, including m3.com, an exclusive information portal for healthcare professionals; MR-kun, which ensures member doctors receive ongoing updates via the m3com platform; QOL-kun, offering non-medical life support; and AskDoctors, where certified physicians address public health inquiries from the general public. Internationally, it operates MDLinx for U.S. medical professionals and Doctorsnetuk, a U.K.-based site supporting pharmaceutical companies and providing drug information databases across France, Germany, and Spain. Furthermore, M3 offers dedicated career services for doctors and pharmacists through its m3com CAREER platform. Its diverse business portfolio extends to sales and marketing for pharmaceutical and medical device companies, as well as the development, sale, and maintenance of electronic medical records and equipment for healthcare facilities. M3 also conducts surveys for medical professionals, offers online sales and marketing assistance to pharmaceutical firms, provides management consulting to medical institutions, delivers home-visit nursing services, and specializes in human resource solutions for healthcare staff, alongside managing clinical trial facilities. Established in 2000, the company was initially named So-netM3, Inc., before rebranding to M3, Inc. in January 2010. Its headquarters are located in Tokyo, Japan.
2413 Stock 12 Month Forecast
Average Price Target
¥2,084.29
▲(9.44% Upside)